Princeton University, BA, 1984
Years in MSTP
Human oncology, 1992
Paul Sondel, MD, PhD
Characterization of the IL-2 Receptors Expressed on Human l Lymphocytes Activated In Vivo During Systemic IL-2 Therapy
Radiology, Beth Israel Deaconess, Boston, 1996-2000
Pediatric radiology, Children's Hospital of Boston, 2000-2001
Associate professor, Department of Radiology, Harvard Medical School, Children's Hospital of Boston
Farner NL, Voss SD, Leary TP, Gan J, Hakimi J, Evans G, Ju G, Sondel PM. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood. 1995 Dec 15;86(12):4568-78. PubMed PMID: 8541547.
Farner NL, Voss SD, Sondel PM. X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Clin Diagn Lab Immunol. 1995 Sep;2(5):518-23. PMID: 8548528; PMCID: PMC170193.
Sondel PM, Voss SD, Hong R. Addendum to SCID, interleukin-2, and the interleukin-2 receptor review. Blood. 1994 Jul 15;84(2):667-8. PMID: 8025293.
Voss SD, Hong R, Sondel PM. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood. 1994 Feb 1;83(3):626-35. PMID: 8298124.
Voss SD, Leary TP, Sondel PM, Robb RJ. Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2428-32. PMID: 7681595; PMCID: PMC46100.
Kaur I, Voss SD, Gupta RS, Schell K, Fisch P, Sondel PM. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J Immunol. 1993 Mar 1;150(5):2046-55. PMID: 8094731.
Voss SD, Sondel PM, Robb RJ. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med. 1992 Aug 1;176(2):531-41. PMID: 1500859; PMCID: PMC2119323.
Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb;11(2):111-8. PMID: 1571333.
Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med. 1990 Oct 1;172(4):1101-14. PMID: 1698909; PMCID: PMC2188601.
Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 1990 May 1;50(9):2683-91. PMID: 1691679.
Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother. 1989;29(4):261-9. PMID: 2787694.
Voss SD, Weil-Hillman G, Hank JA, Sosman JA, Sondel PM. The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull N Y Acad Med. 1989 Jan;65(1):93-110. PMID: 2690996; PMCID: PMC1807781.